Alnylam Expands its Collaboration with Medison Pharma to Commercialize RNAi Therapies
Shots:
- The companies have decided to expand their existing collaboration for RNA interference therapies to several Central & Eastern EU countries. The multi-regional agreement will cover countries incl. Poland, the Czech Republic, Hungary, Slovakia, Lithuania, Estonia & Latvia, in addition to Israel
- The new agreement was based on the long-term collaboration b/w Alnylam & Medison in Israel. The agreement enables Alnylam to use Medison's multi-regional platform for RNAi therapies i.e., Onpattro (patisiran), Givlaari (givosiran) & Oxlumo (lumasiran) across additional countries in EU
- Givlaari & Oxlumo were approved for reimbursement in Poland while both companies will work together to obtain additional reimbursements in the territories
Ref: Prnewswire | Image: Alnylam
Related News:- Alnylam Reports the US FDA’s Acceptance of sNDA Application Filed for Oxlumo to Treat Advanced Primary Hyperoxaluria
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
